Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Bruce Strober, Matthias Augustin, Yayoi Tada, Kimberly Parnell Lafferty, Yevgeniy Krol, Elizabeth Skobelev, Fowzia Ibrahim, Steven Fakharzadeh, Robert GniadeckiBackground
The first phase of the Psoriasis Longitudinal Assessment and Registry (PSOLAR) provided safety, demographic, and other outcomes data from >12,000 patients (>75,000 patient-years) eligible to receive biologics for psoriasis. In 2018, PSOLAR enrollment criteria were updated to specifically include patients receiving either guselkumab or an interleukin-17 inhibitor (IL-17i).
Methods
Baseline characteristics are described for patients included in PSOLAR after adoption of Protocol Amendment 6 (March 26, 2018), which updated enrollment criteria to include patients exposed to guselkumab or an IL-17i.
Results
As of July 12, 2025, 3501 patients (guselkumab, n = 2213; IL-17i, n = 1288) were enrolled at sites in 17 countries. Baseline characteristics were generally balanced between the guselkumab and IL-17i cohorts. The majority of patients were male (59.9%), white (74.3%), and overweight/obese (78.5%; mean [SD] BMI = 30.2 [7.2] kg/m 2 ). Mean (SD) age was 50.3 (13.9) years. On average, patients had longstanding psoriasis at baseline (mean [SD] duration of psoriasis = 19.0 [13.7] years; mean [SD] body surface area = 8.6% [12.7]). Most patients reported current or prior history of alcohol use (77.3%) and smoking (54.1%). Prior to enrollment, most patients (76.9%) reported exposure to ≥1 biologic. Self-reported psoriatic arthritis was less common in the guselkumab vs the IL-17i group (25.0% vs 38.1%).
Conclusion
Patients with psoriasis treated with guselkumab or an IL-17i in this real-world cohort had similar baseline characteristics, although psoriatic arthritis was more common in the IL-17i group. Findings from PSOLAR may help clinicians better understand characteristics of patients who may be prescribed guselkumab or an IL-17i for psoriasis in a real-world setting.
Clinicaltrials.gov Identifier
NCT00508547.